secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2022-12-22T23:59:59+00:00
Accession:  0001104659-22-129343
Event type: litigation
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Federal Circuit upholds Collegium's Belbuca patents; blocks Alvogen generic until 2032
--------------------------------------------------------------------------------

- Alvogen conceded infringement; Federal Circuit ruling bars generic entry until 2032 patent expiry (9,901,539 patent).
- Court upheld validity of claims in '866 (2027) and '539 (2032) patents; remanded some claims of '866 and '843 patents (2027) for reconsideration.
- Decision reinforces strength of Belbuca patent portfolio, protecting key chronic pain product from generic competition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465922129343/0001104659-22-129343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465922129343/tm2233280d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-129343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer